Navigation Links
Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Date:6/19/2012

LONDON, June 19, 2012 /PRNewswire/ -- The Foundation for Research on the Nervous System, Replikins Ltd., and Bioradar UK Ltd. today announced that over 100 new synthetic Replikins vaccines for infectious diseases and cancer are now available as a result of the discovery by scientists Drs. Samuel and Elenore Bogoch of the evolution of the genomic Replikins over time -- from ocean archaea to human cancer. A book on this subject will be released in September 2012.

Peak Gene Replikin Count: http://www.ereleases.com/pic/2012-Peak-Gene-Replikin-Count.jpg

Drs. Bogoch have determined that the highest peak gene Replikin Counts are six-fold greater in brain cancer than the Counts in ocean archaea and viruses. The ability to specify certain increasing genomic sequences related to lethality has permitted new synthetic vaccines for organisms such as Taura Syndrome Virus, infectious salmon anemia virus, universal influenza virus strains, highly lethal drug-resistant tuberculosis, and malaria, and cancers of histological type with the highest five-year mortality rates for which vaccines have not previously been available.

Because these Replikins genomic sequences have been shown to provide 1-2 years advance notice of outbreaks, effective synthetic vaccines have been manufactured by the Companies in seven days, providing time for adequate testing, and can be delivered in freeze-dried form in literally limitless quantities.

References

Accounts of some of the work on individual products have been published 1) in eight papers in Nature Precedings 2011-2012 (http://bit.ly/MdaG8m); 2) on the companies' website (http://www.Replikins.com), which contains over 40 news announcements from 2006-present; and 3) in patent publications from 2002-present.

Contact: Dr. S. Bogoch, 646-320-5910

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer
2. Novel method to make nanomaterials discovered
3. Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria
4. Evolution Issue of the Month 2. Natural Selection--Not the Best Idea Anyone Ever Had
5. Martha Stewart Reveals the Secret Behind her Radiant Skin is Revolutionary Anti-aging BIOEFFECT EGF SERUM
6. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
7. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
8. PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
9. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
10. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
11. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... is proud to announce it has become the premiere team-building cooking event company in San ... world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category on ... to its new team building format, a way for teams to not only interact with ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
Breaking Biology Technology:
(Date:2/24/2017)... Feb. 24, 2017  EyeLock LLC, a leader of iris-based ... iris biometric solution on the latest Qualcomm® Snapdragon™ ... Mobile World Congress 2017 (February 27 – ... Hall 3, Stand 3E10. The ... security platform—a combination of hardware, software and ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):